Central India Chronicle

With the influx of pharmaceutical and Medtech companies along with the novel therapies and devices, the Chronic Venous Insufficiency pipeline is booming

 Breaking News
  • No posts were found

With the influx of pharmaceutical and Medtech companies along with the novel therapies and devices, the Chronic Venous Insufficiency pipeline is booming

September 10
04:31 2021
With the influx of pharmaceutical and Medtech companies along with the novel therapies and devices, the Chronic Venous Insufficiency pipeline is booming
Chronic Venous Insufficiency Pipeline
DelveInsight’s Chronic Venous Insufficiency pipeline report provides an in-depth analysis of the current clinical development landscape and growth prospects for the Chronic Venous Insufficiency industry. The disease summary and Chronic Venous Insufficiency therapy instructions are included in a complete depiction of the Chronic Venous Insufficiency pipeline landscape.

DelveInsight’s Chronic Venous Insufficiency pipeline report provides an in-depth analysis of the current clinical development landscape and growth prospects for the Chronic Venous Insufficiency industry. The disease summary and Chronic Venous Insufficiency therapy instructions are included in a complete depiction of the Chronic Venous Insufficiency pipeline landscape. 

Some of the Important Findings from the Chronic Venous Insufficiency Pipeline Report

  • The Chronic Venous Insufficiency pipeline comprises therapies, as well as devices that are in different stages of the clinical phase, include Sulodexide, TR 987, P-TEV, EndoVenous Valve System (EVVS), InnoVein Valve Treatment, BioVena, VenoValve, and others that are anticipated to launch in the upcoming year and join the Chronic Venous Insufficiency treatment market soon.

  • Key MedTech and pharmaceutical companies involved in developing novel therapies and medical devices for Chronic Venous Insufficiency include Alfasigma, SerenaGroup, Verigraft AB, Venarum Medical, Innovein, Venari Medical, Hancock Jaffe Laboratories, among others.

  • Chronic Venous Insufficiency pipeline therapies that are in late phases i.e Phase III include Sulodexide (Alfasigma), and others whereas TR 987 (SerenaGroup) is in Phase II of clinical trials for Chronic Venous Insufficiency treatment.

  • P-TEV is being developed and investigated in Phase I studies by Verigraft AB for Chronic Venous Insufficiency treatment.

Request for the sample to reach out for more @ Chronic Venous Insufficiency Pipeline Analysis

Chronic Venous Insufficiency: Overview

Chronic Venous Insufficiency (CVI) is a term used to describe lower extremity edema, skin trophic changes, and discomfort caused by venous hypertension. The pathophysiology of chronic venous insufficiency is caused by either reflux (backward flow) or obstruction of venous blood flow. Chronic venous insufficiency can develop as a result of long-term valvular incompetence in the superficial veins, deep veins, or perforating veins that connect them. The end result is venous hypertension of the lower extremities in all cases.

Chronic Venous Insufficiency Symptoms

The most common Chronic Venous Insufficiency symptoms are:

  • Tight feeling in calves or itchy

  • Painful legs

  • Swelling in legs or ankles

  • Painful leg cramps or muscle spasms

  • Varicose veins

  • Leg ulcers

Chronic Venous Insufficiency Treatment

The Chronic Venous Insufficiency treatment focuses on controlling the retrograde flow of blood, venous pooling, and the complications associated with these pathophysiologic processes. Conservative treatment consists of dietary changes, compression therapy with devices, and the administration of venoactive drugs (venopharmaceuticals).

Chronic Venous Insufficiency Pipeline Analysis: Drug Profile

TR 987: SerenaGroup

Product Description

TR-987 (formerly GLYC-101) is an insoluble, microparticulate (13)(16)-glucan extracted from yeast cells in a specific configuration and size. TR-987’s active pharmaceutical ingredient is Glucoprime, a type of glucan known as particulate (1→3)(1→6)-β-glucan. 

Phase II

NCT03154619: SerenaGroup, in collaboration with TR Therapeutics, launched a multi-center, randomized, double-blind, placebo-controlled study in November 2016 to assess the efficacy of TR 987 gel in the treatment of chronic venous insufficiency ulcers.

Chronic Venous Insufficiency Pipeline Analysis: Medical Device Profile

VenoValve: Hancock Jaffe Laboratories

Product Description

VenoValve is a bioprosthetic venous valve that improves chronic lower extremity venous reflux via an open surgical procedure. The company is conducting a prospective, non-blind, single-arm, multicenter study to evaluate the safety and efficacy of the VenoValve, which is surgically implanted into the deep venous system to treat patients with deep venous valvular insufficiency.

Chronic Venous Insufficiency Pipeline Therapies/Devices and Key Companies 

  • Sulodexide: Alfasigma

  • TR 987: SerenaGroup

  • P-TEV: Verigraft AB

  • EndoVenous Valve System (EVVS): Venarum Medical

  • InnoVein Valve Treatment: Innovein

  • BioVena: Venari Medical

  • VenoValve: Hancock Jaffe Laboratories

For more information on the emerging drugs/devices and companies, visit Chronic Venous Insufficiency Clinical Trails

Chronic Venous Insufficiency Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

    • Protease

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

    • Multiple Kinase Inhibitor

Chronic Venous Insufficiency Medical Device Assessment

  • By Stage

    • Pre-clinical

    • Clinical

  • By Patient Type

    • Pediatric

    • Adult

Scope of the Report

Coverage: Global

Chronic Venous Insufficiency Key Players: Alfasigma, SerenaGroup, Verigraft AB, Venarum Medical, Innovein, Venari Medical, Hancock Jaffe Laboratories, among others

Chronic Venous Insufficiency Pipeline Therapies/Devices: Sulodexide, TR 987, P-TEV, EndoVenous Valve System (EVVS), InnoVein Valve Treatment, BioVena, VenoValve, and others

Table of Contents

1.

Introduction

2.

Executive Summary

3.

Chronic Venous Insufficiency: Overview

4.

Chronic Venous Insufficiency Pipeline Therapeutics

5.

Chronic Venous Insufficiency Late Stage Products (Pre-registration)

6.

Chronic Venous Insufficiency Late Stage Products (Phase  III)

7.

Chronic Venous Insufficiency Mid Stage Products (Phase  II)

8.

Chronic Venous Insufficiency Early Stage Products (Phase  I)

9.

Chronic Venous Insufficiency Pre-clinical and Discovery Stage Products

10.

Chronic Venous Insufficiency Pipeline Medical devices: Company Profiles

11.

Chronic Venous Insufficiency Therapeutic Assessment

12.

Chronic Venous Insufficiency Medical Device Assessment

13.

Chronic Venous Insufficiency Inactive Products

14.

Chronic Venous Insufficiency- Market Drivers and Barriers

15.

Chronic Venous Insufficiency- Unmet Needs

16.

Appendix

17.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Key questions answered in the Chronic Venous Insufficiency Pipeline Report

  • What are the available treatments for Chronic Venous Insufficiency?

  • How many pharmaceutical and Medtech companies are developing treatments for Chronic Venous Insufficiency?

  • Which of these firms’ pharmaceuticals is the most widely used?

  • How many Chronic Venous Insufficiency medications/devices does each company produce?

  • How many drugs/devices for Chronic Venous Insufficiency are in the early, mid, or late stages of development?

  • How many of the currently being developed therapies/devices can be used alone or in combination with other treatments?

  • What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices affecting Chronic Venous Insufficiency?

Related Reports

Exocrine Pancreatic Insufficiency Pipeline Insights

Get a comprehensive analysis of Exocrine Pancreatic Insufficiency pipeline therapies and key companies including Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles